Generated by AI
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing precision medicines for genetically defined cancers. The company’s current programs center on small-molecule MasterKey therapies designed to target families of oncogenic mutations across multiple tumor types, with an emphasis on overcoming resistance and addressing tumors that are difficult to treat with standard approaches. Its lead clinical asset, silevertinib, is a brain-penetrant EGFR inhibitor being studied in non-small cell lung cancer and glioblastoma. Black Diamond Therapeutics also advances additional oncology candidates in its pipeline aimed at other mutation-driven solid tumors. Based in Cambridge, Massachusetts, the company plays a role in the biotechnology market as a developer of targeted cancer therapies intended for patients whose tumors are driven by specific genetic alterations.
Website245 First Street
Cambridge, MA, 02142
United States
The latest articles about BDTX.
(AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $10 million in its third quarter.
Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Summary of Apr 1's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Investors talking about BDTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.